Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

• Autores principales: Seiichi Hayato (Autor), Osamu Takenaka (Autor), Sree Harsha Sreerama Reddy (Autor), Ishani Landry (Autor), Larisa Reyderman (Autor), Akihiko Koyama (Autor), Chad Swanson (Autor), Sanae Yasuda (Autor), Ziad Hussein (Autor)
• Formato: Libro
• Publicado: Wiley, 2022-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharmacodynamic (PD) analyses for amyloid plaques, as mea...